Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 346

Similar articles for PubMed (Select 10895822)

1.

Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?

Horenstein MG, Prieto VG, Nuckols JD, Burchette JL, Shea CR.

Am J Surg Pathol. 2000 Jul;24(7):996-1003.

PMID:
10895822
3.

CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.

Goldblum JR, Tuthill RJ.

Am J Dermatopathol. 1997 Apr;19(2):147-53.

PMID:
9129699
4.
5.
7.

Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data--a study from the French Federation of Cancer Centers Sarcoma Group.

Terrier-Lacombe MJ, Guillou L, Maire G, Terrier P, Vince DR, de Saint Aubain Somerhausen N, Collin F, Pedeutour F, Coindre JM.

Am J Surg Pathol. 2003 Jan;27(1):27-39.

PMID:
12502925
8.

Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.

Kim HJ, Lee JY, Kim SH, Seo YJ, Lee JH, Park JK, Kim MH, Cinn YW, Cho KH, Yoon TY.

Br J Dermatol. 2007 Aug;157(2):319-24. Epub 2007 Jun 26. Review.

PMID:
17596171
9.
10.

Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.

Mori T, Misago N, Yamamoto O, Toda S, Narisawa Y.

J Dermatol. 2008 Jul;35(7):419-25. doi: 10.1111/j.1346-8138.2008.00496.x.

PMID:
18705829
11.

[Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].

Xiong Y, Guo H, Zhang S, Zhang B, Li T.

Beijing Da Xue Xue Bao. 2008 Aug 18;40(4):395-400. Chinese.

12.

Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.

Zelger BW, Ofner D, Zelger BG.

Histopathology. 1995 Jun;26(6):519-27.

PMID:
7545142
13.

Dermatofibrosarcoma protuberans: a clinicopathological analysis of 10 cases in Asians.

Tan AW, Tan SH.

Australas J Dermatol. 2004 Feb;45(1):29-33.

PMID:
14961905
14.

The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans.

Abbott JJ, Oliveira AM, Nascimento AG.

Am J Surg Pathol. 2006 Apr;30(4):436-43.

PMID:
16625088
15.

Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.

West KL, Cardona DM, Su Z, Puri PK.

Am J Dermatopathol. 2014 May;36(5):414-9. doi: 10.1097/DAD.0b013e3182a70396.

PMID:
24162384
16.

Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.

Mentzel T, Schärer L, Kazakov DV, Michal M.

Am J Dermatopathol. 2007 Oct;29(5):443-8.

PMID:
17890911
17.
18.

COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.

Wang WL, Patel KU, Coleman NM, Smith-Zagone MJ, Ivan D, Reed JA, López-Terrada D, Lazar AJ, Prieto VG.

Am J Dermatopathol. 2010 Apr;32(2):149-53. doi: 10.1097/DAD.0b013e3181b0b876.

PMID:
19940748
19.

Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases.

Reimann JD, Fletcher CD.

Am J Surg Pathol. 2007 Sep;31(9):1371-7.

PMID:
17721193
20.

D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.

Bandarchi B, Ma L, Marginean C, Hafezi S, Zubovits J, Rasty G.

Mod Pathol. 2010 Mar;23(3):434-8. doi: 10.1038/modpathol.2009.176. Epub 2010 Jan 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk